预测持续性低氧性呼吸衰竭模型的开发与外部验证:用于临床试验富集
该研究在美国两个医学中心的医疗与外科ICU前瞻性纳入成人急性低氧性呼吸衰竭患者,开发队列630例、外部验证队列511例,定义持续性HRF为入住后第三个日历日仍需有创机械通气且存在低氧血症。开发了三个模型:LASSO临床模型(纳入PaO2/FiO2、血管升压药、平均动脉压、碳酸氢盐、ARDS)、在临床预测因子上加IL-6的模型、以及单用PaO2/FiO2的对照模型。验证队列中持续性HRF发生率为69%(开发队列49%),LASSO模型AUC 0.68(95%CI 0.64-0.73)、LASSO+IL-6模型AUC 0.71(95%CI 0.66-0.76),均优于单用PaO2/FiO2的AUC 0.64(95%CI 0.59-0.69);两模型在较低风险十分位低估风险,但在相关风险阈值处校准更好。决策曲线分析显示两模型净获益更大,富集分析显示可节省更多样本量,LASSO+IL-6较LASSO的额外效用有限。作者认为这些简约、可解释的模型可能改善针对HRF靶向治疗的试验富集,并需未来验证。
要点
- 验证队列中持续性HRF(入住后第三个日历日仍需IMV且低氧血症)发生率为69%,开发队列为49%。
- 外部验证中LASSO模型AUC 0.68(95%CI 0.64-0.73)、LASSO+IL-6模型AUC 0.71(95%CI 0.66-0.76),均优于单用PaO2/FiO2的AUC 0.64(95%CI 0.59-0.69)。
- LASSO模型选择PaO2/FiO2、血管升压药、平均动脉压、碳酸氢盐和ARDS为预测因子。
- 两模型在较低风险十分位低估风险,但在相关风险阈值处校准更好。
- 与单用PaO2/FiO2相比,LASSO和LASSO+IL-6模型在决策曲线分析中净获益更大、在富集分析中样本量节省更多;LASSO+IL-6较LASSO的额外效用有限。
适用人群与场景
- 美国两个医学中心医疗与外科ICU的成人患者,急性低氧性呼吸衰竭定义为入住ICU后第一个日历日新接受有创机械通气并存在低氧血症。
- 开发队列n=630,外部验证队列n=511。
诊断标准与关键阈值
- 持续性低氧性呼吸衰竭定义为入住后第三个日历日仍需有创机械通气且存在低氧血症。
研究设计与关键结果
- 研究设计:前瞻性开发队列(n=630)与外部验证队列(n=511),美国两个医学中心医疗与外科ICU,无干预。
- 持续性HRF发生率:开发队列49%,验证队列69%。
- 外部验证判别力:LASSO模型AUC 0.68(95%CI 0.64-0.73),LASSO+IL-6模型AUC 0.71(95%CI 0.66-0.76),单用PaO2/FiO2模型AUC 0.64(95%CI 0.59-0.69)。
- 校准:两模型在较低风险十分位低估风险,但在相关风险阈值处校准更好。
- 实用效用:与单用PaO2/FiO2相比,LASSO和LASSO+IL-6模型在决策曲线分析中净获益更大,在富集分析中样本量节省更多;LASSO+IL-6较LASSO的额外效用有限。
证据类型、等级与局限
- 证据类型:前瞻性队列研究(开发队列与外部验证队列)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,预测持续性HRF的简约、可解释模型可能改善针对HRF靶向治疗的试验富集,并需未来验证。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Improving the efficiency of clinical trials in acute hypoxemic respiratory failure (HRF) depends on enrichment strategies that minimize enrollment of patients who quickly resolve with existing care and focus on patients at high risk for persistent HRF. We aimed to develop parsimonious models predicting risk of persistent HRF using routine data from ICU admission and select research immune biomarkers.
DESIGN: Prospective cohorts for derivation ( n = 630) and external validation ( n = 511).
SETTING: Medical and surgical ICUs at two U.S. medical centers.
PATIENTS: Adults with acute HRF defined as new invasive mechanical ventilation (IMV) and hypoxemia on the first calendar day after ICU admission.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: We evaluated discrimination, calibration, and practical utility of models predicting persistent HRF risk (defined as ongoing IMV and hypoxemia on the third calendar day after admission): 1) a clinical model with least absolute shrinkage and selection operator (LASSO) selecting Pa o2 /F io2 , vasopressors, mean arterial pressure, bicarbonate, and acute respiratory distress syndrome as predictors; 2) a model adding interleukin-6 (IL-6) to clinical predictors; and 3) a comparator model with Pa o2 /F io2 alone, representing an existing strategy for enrichment. Forty-nine percent and 69% of patients had persistent HRF in derivation and validation sets, respectively. In validation, both LASSO (area under the receiver operating characteristic curve, 0.68; 95% CI, 0.64-0.73) and LASSO + IL-6 (0.71; 95% CI, 0.66-0.76) models had better discrimination than Pa o2 /F io2 (0.64; 95% CI, 0.59-0.69). Both models underestimated risk in lower risk deciles, but exhibited better calibration at relevant risk thresholds. Evaluating practical utility, both LASSO and LASSO + IL-6 models exhibited greater net benefit in decision curve analysis, and greater sample size savings in enrichment analysis, compared with Pa o2 /F io2 . The added utility of LASSO + IL-6 model over LASSO was modest.
CONCLUSIONS: Parsimonious, interpretable models that predict persistent HRF may improve enrichment of trials testing HRF-targeted therapies and warrant future validation.
参考来源
- Sathe NA, Zelnick LR, Morrell ED, et al. Development and External Validation of Models to Predict Persistent Hypoxemic Respiratory Failure for Clinical Trial Enrichment. Crit Care Med. 2024. PMID: 38197736. doi:10.1097/CCM.0000000000006181
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。